DepoCyte

RSS

cytarabine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for DepoCyte has been withdrawn at the request of the marketing authorisation holder. 

This EPAR was last updated on 07/10/2019

Authorisation details

Product details
Name
DepoCyte
Agency product number
EMEA/H/C/000317
Active substance
cytarabine
International non-proprietary name (INN) or common name
cytarabine
Therapeutic area (MeSH)
Meningeal Neoplasms
Anatomical therapeutic chemical (ATC) code
L01BC01
Publication details
Marketing-authorisation holder
Pacira Limited
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
11/07/2001
Contact address
3 Glory Park Avenue
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0DF
United Kingdom

Product information

26/06/2017 DepoCyte - EMEA/H/C/000317 - N/0059

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings